Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells

被引：1
|
作者：
Elena E. Tzekaki
George Geromichalos
Sophia N. Lavrentiadou
Maria P. Tsantarliotou
Anastasia A. Pantazaki
Angelos Papaspyropoulos
机构：
[1] Aristotle University of Thessaloniki,Laboratory of Biochemistry, Department of Chemistry
[2] Aristotle University of Thessaloniki,School of Veterinary Medicine
来源：
Breast Cancer Research and Treatment | 2021年 / 186卷
关键词：
Plasminogen activator inhibitor-1 (PAI-1); Extra virgin olive oil (EVOO); Oleuropein; ER/PR-responsive human cancer; MDA-MB-231; MCF-7;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：305 / 316
页数：11
相关论文
共 50 条
  • [1] Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells
    Tzekaki, Elena E.
    Geromichalos, George
    Lavrentiadou, Sophia N.
    Tsantarliotou, Maria P.
    Pantazaki, Anastasia A.
    Papaspyropoulos, Angelos
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (02) : 305 - 316
  • [2] Hip circumference is associated with the risk of premenopausal ER-/PR- breast cancer
    Fagherazzi, G.
    Chabbert-Buffet, N.
    Fabre, A.
    Guillas, G.
    Boutron-Ruault, M-C
    Mesrine, S.
    Clavel-Chapelon, F.
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (03) : 431 - 439
  • [3] EFFECTS OF RESVERATROL ON TRIPLE NEGATIVE (ER-, PR-, HER2-) BREAST CANCER CELLS
    Mangum, Carla
    Cameron, Joseph A.
    Herbert, Brittney-Shea
    [J]. FASEB JOURNAL, 2008, 22
  • [4] An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells
    Novikov, Olga
    Wang, Zhongyan
    Stanford, Elizabeth A.
    Parks, Ashley J.
    Ramirez-Cardenas, Alejandra
    Landesman, Esther
    Laklouk, Israa
    Sarita-Reyes, Carmen
    Gusenleitner, Daniel
    Li, Amy
    Monti, Stefano
    Manteiga, Sara
    Lee, Kyongbum
    Sherr, David H.
    [J]. MOLECULAR PHARMACOLOGY, 2016, 90 (05) : 674 - 688
  • [5] Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival
    Roseland, M. E.
    Schwartz, K.
    Ruterbusch, J. J.
    Lamerato, L.
    Krajenta, R.
    Booza, J.
    Simon, Michael S.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (01) : 163 - 168
  • [6] Comparison of the sensitivity to endocrine therapy of PR plus /ER- patients and ER plus /PR- patients with HER2+breast cancer
    Hao, X.
    Liu, Y.
    Hui, R.
    Zhang, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] ER Stress marker GRP78 is not expressed on ER-/PR-/Her2- human breast cancer cell surface or secreted
    Serrano, Jesus E.
    Rivera-Ruiz, Andrea
    Baksi, Krishna
    Banerjee, Dipak K.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [8] ER Stress marker GRP78 is not expressed on ER-/PR-/Her2- human breast cancer cell surface or secreted
    Banerjee, Dipak K.
    Negron, Jesus E. Serrano
    Ruiz, Andrea Rivera
    Baksi, Krishna
    [J]. FASEB JOURNAL, 2018, 32 (01):
  • [9] Quantifying the relative value of drug therapy options in HER2+, ER-/PR- breast cancer
    Whang, John
    Steinkellner, Amy R.
    Borne, Jane M.
    Piana, Elizabeth N.
    Wong, Winston
    Aubert, Ronald E.
    Selby, Norman C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] GRP78 is Neither Expressed on ER-/PR-/Her2- Human Breast Cancer Cell Surface nor Secreted
    Serrano, Jesus E.
    Romero-Nutz, Eva C.
    Sanchez, Neysharie
    Banerjee, Aditi
    Baksi, Krishna
    Banerjee, Dipak K.
    [J]. FASEB JOURNAL, 2017, 31
12345